Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.28 EUR | +3.24% | -4.00% | -13.37% |
May. 28 | SCHOTT PHARMA : Berenberg reiterates its Neutral rating | ZD |
May. 21 | Deutsche Bank Research lowers target for Schott Pharma - 'Buy' | DP |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.36 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.72 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.37% | 4.79B | - | ||
-7.16% | 178B | C+ | ||
-1.23% | 107B | C | ||
-4.86% | 67.04B | A | ||
-4.28% | 47.23B | B- | ||
+10.32% | 44.62B | B- | ||
+8.14% | 42.5B | B+ | ||
+15.53% | 25.22B | A- | ||
-5.88% | 24.14B | A- | ||
-5.38% | 23.69B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1SXP Stock
- 1SXP Stock
- Ratings SCHOTT Pharma AG & Co. KGaA